Artal Group’s Celgene Corp CELG Stock Holding History

Artal Group’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-750,000	Closed	-$70.8M	–	129
2019 Q1	$70.8M	Sell	750,000 -250,000	-25%	-$21.9M	2.89%	8
2018 Q4	$64.1M	Buy	1,000,000 +250,000	+33%	+$18.5M	2.37%	8
2018 Q3	$67.1M	Sell	750,000 -1,250,000	-63%	-$110M	1.75%	10
2018 Q2	$159M	Buy	2,000,000 +1,350,000	+208%	+$112M	3.38%	4
2018 Q1	$58M	Buy	650,000 +500,000	+333%	+$48M	0.73%	14
2017 Q4	$15.7M	Buy	+150,000	New	+$16.9M	0.24%	37
2017 Q2	–	Sell	-250,000	Closed	-$31.1M	–	119
2017 Q1	$31.1M	Sell	250,000 -450,000	-64%	-$53.9M	0.69%	12
2016 Q4	$81M	Hold	700,000	–	–	1.8%	5
2016 Q3	$73.2M	Buy	700,000 +500,000	+250%	+$54.1M	1.45%	6
2016 Q2	$19.7M	Sell	200,000 -100,000	-33%	-$10.3M	0.41%	17
2016 Q1	$30M	Sell	300,000 -500,000	-63%	-$51.5M	0.59%	15
2015 Q4	$95.8M	Buy	800,000 +150,000	+23%	+$17.4M	1.8%	7
2015 Q3	$70.3M	Buy	650,000 +50,000	+8%	+$6.2M	1.57%	8
2015 Q2	$69.4M	Buy	600,000 +300,000	+100%	+$34.3M	2.99%	6
2015 Q1	$34.6M	Buy	+300,000	New	+$35.8M	1.6%	18

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Artal Group's CELG Position: Q1 2017 in Review

Artal Group sold out of Celgene Corp (CELG) in Q1 2017, closing a stake of 100,000 shares — an estimated $12M sold.

Artal Group first reported a position in CELG in Q4 2015 and held it in 3 quarters. The position peaked at $36M in Q1 2016. 1,417 funds tracked by Wall St. Rank hold CELG as of Q1 2017.

Artal Group reported no remaining Celgene Corp position as of Q1 2017 after selling out during the quarter.
Artal Group sold 100,000 Celgene Corp shares in Q1 2017, an estimated $12M.
Artal Group first reported a position in Celgene Corp in Q4 2015 and held it in 3 quarters.
Artal Group's Celgene Corp position peaked at $36M in Q1 2016.
1,417 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2017.

Based on Artal Group's 13F filing for Q1 2017, filed 15 May 2017.